EUVIMEDEUVIMED entdecken
Fallbericht

Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa

Justine H Ryu, Kenneth A Bauer, Sol Schulman

Journal of Thrombosis and Haemostasis · 2023

DOI: 10.1016/j.jtha.2023.09.009 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Justine H Ryu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; Division of Hemat…. Hauptthemen laut MEDLINE: von Willebrand Disease, Type 2, Hemostatics, Hemophilia A, von Willebrand Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Novo Nordisk, Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 Normandy von Willebrand disease (type 2N VWD) is a rare qualitative defect in von Willebrand factor (VWF) that results in impaired factor VIII (FVIII) binding and consequently reduced FVIII levels. Current perioperative strategies require VWF concentrates to attain durable hemostatic FVIII levels. This case highlights the successful perioperative management of a 78-year-old female with type 2N VWD and coronary artery disease utilizing efanesoctocog alfa, a novel long-acting recombinant FVIII product approved for hemophilia A. By decoupling the FVIII-VWF interaction, efanesoctocog alfa achieves prolonged FVIII circulation independent of VWF. A single administration targeting 90% FVIII levels yielded sustained FVIII elevation without achieving supraphysiologic VWF levels, thus mitigating potential cardiovascular risks. This is the first report of efanesoctocog alfa use in type 2N VWD. Further clinical studies are necessary to corroborate its efficacy and safety for this indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand Disease, Type 2HemostaticsHemophilia Avon Willebrand DiseasesFemaleHumansAgedvon Willebrand FactorFactor VIIIHemostasis

Stichwörter der Autor:innen

blood coagulationfactor VIIIhemostasisvon Willebrand diseasevon Willebrand factor

Substanzen

von Willebrand FactorFactor VIIIHemostatics

Autor:innen und Institutionen

  • Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Cent…

Förderung

  • Novo Nordisk
  • Genentech

Zitieren

APA

Ryu, J. H., Bauer, K. A., & Schulman, S. (2023). Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.09.009

Vancouver

Ryu JH, Bauer KA, Schulman S. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.09.009

BibTeX
@article{Ryu2023,
  author = {Ryu, Justine H and Bauer, Kenneth A and Schulman, Sol},
  title = {Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  doi = {10.1016/j.jtha.2023.09.009}
}
Kostenlos starten →